NO20001515L - Vitronectin receptor antagonist - Google Patents
Vitronectin receptor antagonistInfo
- Publication number
- NO20001515L NO20001515L NO20001515A NO20001515A NO20001515L NO 20001515 L NO20001515 L NO 20001515L NO 20001515 A NO20001515 A NO 20001515A NO 20001515 A NO20001515 A NO 20001515A NO 20001515 L NO20001515 L NO 20001515L
- Authority
- NO
- Norway
- Prior art keywords
- receptor antagonist
- vitronectin receptor
- vitronectin
- osteoporosis
- useful
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
En forbindelse med formel (I) er beskrevet som er en vitronektin-reseptorantagonist og er nyttige ved behandling av osteoporose: eller et farmasøytisk godtagbart salt derav.A compound of formula (I) is disclosed which is a vitronectin receptor antagonist and useful in the treatment of osteoporosis: or a pharmaceutically acceptable salt thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5986797P | 1997-09-24 | 1997-09-24 | |
PCT/US1998/019987 WO1999015178A1 (en) | 1997-09-24 | 1998-09-24 | Vitronectin receptor antagonist |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20001515L true NO20001515L (en) | 2000-03-23 |
NO20001515D0 NO20001515D0 (en) | 2000-03-23 |
Family
ID=22025805
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20001515A NO20001515D0 (en) | 1997-09-24 | 2000-03-23 | Vitronectin receptor antagonist |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1023073A1 (en) |
JP (1) | JP2002500162A (en) |
KR (1) | KR20010024249A (en) |
CN (1) | CN1271284A (en) |
AU (1) | AU9578798A (en) |
BR (1) | BR9813214A (en) |
CA (1) | CA2304000A1 (en) |
HU (1) | HUP0003931A2 (en) |
IL (1) | IL135188A0 (en) |
NO (1) | NO20001515D0 (en) |
PL (1) | PL339414A1 (en) |
TR (1) | TR200000786T2 (en) |
WO (1) | WO1999015178A1 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1150965A4 (en) | 1999-02-03 | 2002-05-15 | Merck & Co Inc | Benzazepine derivatives as alpha-v integrin receptor antagonists |
US6514964B1 (en) | 1999-09-27 | 2003-02-04 | Amgen Inc. | Fused cycloheptane and fused azacycloheptane compounds and their methods of use |
EP1381384B1 (en) | 2001-04-24 | 2011-05-25 | Merck Patent GmbH | COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNFalpha |
WO2003059251A2 (en) | 2001-10-22 | 2003-07-24 | The Scripps Research Institute | Antibody targeting compounds |
EP1628949A4 (en) | 2003-04-04 | 2008-07-02 | Smithkline Beecham Corp | Process and intermediates for preparing benzazepines |
CA2554644C (en) | 2004-02-02 | 2015-06-16 | Pioneer Hi-Bred International, Inc. | Ap2 domain transcription factor odp2 (ovule development protein 2) and methods of use |
UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
EP2335733B1 (en) | 2006-01-18 | 2014-08-06 | Merck Patent GmbH | Specific therapy using integrin ligands for treating cancer |
CN101588812A (en) | 2007-01-18 | 2009-11-25 | 默克专利有限公司 | Specific therapy and medicament using integrin ligands for treating cancer |
CA2705916C (en) | 2007-11-16 | 2016-01-05 | Ube Industries, Ltd. | Benzazepinone compound |
WO2009111679A2 (en) * | 2008-03-06 | 2009-09-11 | Smithkline Beecham Corporation | Process |
WO2010093706A2 (en) | 2009-02-10 | 2010-08-19 | The Scripps Research Institute | Chemically programmed vaccination |
US20120095215A1 (en) | 2009-03-30 | 2012-04-19 | Ube Industries, Ltd. | Medical composition for treatment or prophylaxis of eye diseases |
WO2010136168A2 (en) | 2009-05-25 | 2010-12-02 | Merck Patent Gmbh | Continuous administration of integrin ligands for treating cancer |
AU2010339404B2 (en) | 2009-12-30 | 2016-01-28 | Pioneer Hi-Bred International, Inc. | Methods and compositions for the introduction and regulated expression of genes in plants |
AU2010339481B2 (en) | 2009-12-30 | 2016-02-04 | Pioneer Hi-Bred International, Inc. | Methods and compositions for targeted polynucleotide modification |
EP3148587B1 (en) | 2014-05-30 | 2021-02-24 | Pfizer Inc | Carbonitrile derivatives as selective androgen receptor modulators |
WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA60311C2 (en) * | 1996-10-02 | 2003-10-15 | Смітклайн Бічам Корпорейшн | Vitronectin receptor antagonists |
-
1998
- 1998-09-24 CA CA002304000A patent/CA2304000A1/en not_active Abandoned
- 1998-09-24 BR BR9813214-8A patent/BR9813214A/en not_active Application Discontinuation
- 1998-09-24 AU AU95787/98A patent/AU9578798A/en not_active Abandoned
- 1998-09-24 CN CN98809494A patent/CN1271284A/en active Pending
- 1998-09-24 HU HU0003931A patent/HUP0003931A2/en unknown
- 1998-09-24 WO PCT/US1998/019987 patent/WO1999015178A1/en not_active Application Discontinuation
- 1998-09-24 TR TR2000/00786T patent/TR200000786T2/en unknown
- 1998-09-24 KR KR1020007003093A patent/KR20010024249A/en not_active Application Discontinuation
- 1998-09-24 EP EP98949471A patent/EP1023073A1/en active Pending
- 1998-09-24 PL PL98339414A patent/PL339414A1/en unknown
- 1998-09-24 JP JP2000512547A patent/JP2002500162A/en not_active Withdrawn
- 1998-09-24 IL IL13518898A patent/IL135188A0/en unknown
-
2000
- 2000-03-23 NO NO20001515A patent/NO20001515D0/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
HUP0003931A2 (en) | 2001-10-28 |
JP2002500162A (en) | 2002-01-08 |
WO1999015178A1 (en) | 1999-04-01 |
PL339414A1 (en) | 2000-12-18 |
CN1271284A (en) | 2000-10-25 |
KR20010024249A (en) | 2001-03-26 |
EP1023073A1 (en) | 2000-08-02 |
NO20001515D0 (en) | 2000-03-23 |
CA2304000A1 (en) | 1999-04-01 |
AU9578798A (en) | 1999-04-12 |
IL135188A0 (en) | 2001-05-20 |
TR200000786T2 (en) | 2000-08-21 |
BR9813214A (en) | 2000-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20001515L (en) | Vitronectin receptor antagonist | |
NO20001514L (en) | Vitronectin receptor antagonist | |
NO983002L (en) | Vitronectin receptor antagonists | |
NO983003L (en) | Vitronectin receptor antagonists | |
NO20025821L (en) | 2-aminocarbonyl-9H-purine | |
IL133623A0 (en) | Antithrombotic agents | |
EP0999834A4 (en) | Antithrombotic agents | |
DK0896533T3 (en) | Pentafluorobenzene sulfonamides and analogues | |
GB9514473D0 (en) | Chemical compounds | |
FI964815A0 (en) | Piperazine derivatives as 5-HT1A antagonists | |
IL165262A (en) | Kinase inhibitors and pharmaceutical compositions containing them | |
SG44989A1 (en) | Crystalline hydrochloride of (R)-(-)-2-{N-[4-(1,1-dioxid-3-oxo-2,3-dihydro-benzisothiazol-2-yl)-butyl]-aminomethyl}-chroman | |
DE60121461D1 (en) | CONDENSED PYRIDOINDOL DERIVATIVES | |
BR9812340A (en) | Vitronectin receptor antagonists | |
NO975975L (en) | Vitronectin receptor antagonists, preparation and use thereof | |
ATE240339T1 (en) | NUCLEOTIDE ANALOGUES | |
ATE359793T1 (en) | 2-METHYL-THIENO-BENZODIAZEPINE FORMULATION | |
AP1534A (en) | Vitronectin receptor antagonists. | |
WO1998031704A3 (en) | Tachykinin antagonists | |
WO2001017959A3 (en) | Vitronectin receptor antagonists | |
NO20004545L (en) | Process for the preparation of (R) - <alpha> - (2,3-dimethoxyphenyl) -1- [2- (4-fluorophenyl) ethyl] -4-piperidinemethanol | |
WO2000007544A3 (en) | Vitronectin receptor antagonists | |
NO306673B1 (en) | Intermediate for the preparation of pharmaceutically active compound | |
NO953480L (en) | Use and Method of Treatment Using Carbazolyl (4) Oxypropylamine Compounds for Inhibition of Smooth Muscle Cell Propagation | |
IT1303687B1 (en) | USE OF GAMMA HYDROXYBUTIRRIC ACID OR ITS PHARMACEUTICALLY ACCEPTABLE SALT FOR ISCHEMIA TREATMENT |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |